GlassScriptPhysician profile
Ashish Goel
NPI 1740285964
$1,114.54
in general payments reported to CMS, 2019-2025
15 companies · $280 in 2025
The $280 reported for 2025 was more than what 86% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $133 · 2021: $157 · 2022: $34.36 · 2023: $285 · 2024: $226 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $440.28 | 2023-2025 | Tremfya, Stelara, Simponi |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Alkermes, INC. | $109.54 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.84 | 2021-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $72.36 | 2024-2025 | Omvoh |
| Cumberland Pharmaceuticals, INC. | $60.34 | 2023-2024 | Kristalose |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.85 | 2022-2023 | Xifaxan |
| Braintree Laboratories, INC. | $37.61 | 2023 | Sutab |
| Qol Medical, LLC | $37.51 | 2025 | Sucraid |
| Abbvie INC. | $23.22 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.85 | 2023 | Voquezna |
| Aimmune Therapeutics, INC. | $18.29 | 2025 | Vowst |
| W. L. Gore & Associates, INC. | $15.84 | 2023 | Gore Cardioform Septal Occluder |
| Intercept Pharmaceuticals, INC. | $14.18 | 2022 | |
| Ardelyx, INC. | $12.83 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Goel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.